These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23946627)

  • 1. Nuedexta for the treatment of pseudobulbar affect: a condition of involuntary crying or laughing.
    Cruz MP
    P T; 2013 Jun; 38(6):325-8. PubMed ID: 23946627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dextromethorphan/quinidine for the treatment of pseudobulbar affect.
    Patatanian E; Casselman J
    Consult Pharm; 2014 Apr; 29(4):264-9. PubMed ID: 24704895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of pseudobulbar affect in a mixed neurodegenerative disorder with compounded quinidine capsules and dextromethorphan cough syrup.
    Villeneuve Y; Cruz-Santiago D; Masson H; Clerc D
    SAGE Open Med Case Rep; 2020; 8():2050313X20921076. PubMed ID: 32547756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crying and suicidal, but not depressed. Pseudobulbar affect in multiple sclerosis successfully treated with valproic acid: Case report and literature review.
    Johnson B; Nichols S
    Palliat Support Care; 2015 Dec; 13(6):1797-801. PubMed ID: 24916672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of pseudobulbar affect (PBA) in a patient with a history of traumatic brain injury, partial brain resection, and brainstem stroke: a case report.
    Young FG; Nguyen D
    J Med Case Rep; 2020 Dec; 14(1):235. PubMed ID: 33272325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dextromethorphan/quinidine: in pseudobulbar affect.
    Garnock-Jones KP
    CNS Drugs; 2011 May; 25(5):435-45. PubMed ID: 21476614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Approach of a High Functioning Individual With Traumatic Brain Injury and Subsequent Emotional Volatility With Features of Pathological Laughter and Crying With Dextromethorphan/Quinidine.
    Garcia-Baran D; Johnson TM; Wagner J; Shen J; Geers M
    Medicine (Baltimore); 2016 Mar; 95(12):e2886. PubMed ID: 27015166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect.
    Pioro EP
    Neurol Ther; 2014 Jun; 3(1):15-28. PubMed ID: 26000221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dextromethorphan/quinidine (Nuedexta) for pseudobulbar affect.
    Med Lett Drugs Ther; 2011 Jun; 53(1366):46-7. PubMed ID: 21659969
    [No Abstract]   [Full Text] [Related]  

  • 10. A Major Depressive Disorder in a Patient with Pseudobulbar Affect.
    Espiridion ED; Risos KN
    Cureus; 2018 Dec; 10(12):e3746. PubMed ID: 30820367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Compounded Dextromethorphan-Quinidine Suspension for Pseudobulbar Affect in Hospice Patients.
    Wahler RG; Reiman AT; Schrader JV
    J Palliat Med; 2017 Mar; 20(3):294-297. PubMed ID: 27997281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.
    Panitch HS; Thisted RA; Smith RA; Wynn DR; Wymer JP; Achiron A; Vollmer TL; Mandler RN; Dietrich DW; Fletcher M; Pope LE; Berg JE; Miller A;
    Ann Neurol; 2006 May; 59(5):780-7. PubMed ID: 16634036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.
    Brooks BR; Thisted RA; Appel SH; Bradley WG; Olney RK; Berg JE; Pope LE; Smith RA;
    Neurology; 2004 Oct; 63(8):1364-70. PubMed ID: 15505150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NueDexta: A Treatment for Pseudobulbar Affect.
    Roman MW
    Issues Ment Health Nurs; 2015; 36(12):1019-21. PubMed ID: 26735510
    [No Abstract]   [Full Text] [Related]  

  • 15. Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect.
    Yang LP; Deeks ED
    Drugs; 2015 Jan; 75(1):83-90. PubMed ID: 25420446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudobulbar Affect Mimicking Depression: A Case Report.
    Kekere V; Qureshi D; Thanju A; Fouron P; Olupona T
    Cureus; 2022 Jun; 14(6):e26235. PubMed ID: 35911367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recognizing and treating pseudobulbar affect.
    Sauvé WM
    CNS Spectr; 2016 Dec; 21(S1):34-44. PubMed ID: 28044945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of pseudobulbar affect symptoms in the nursing home setting: Development and assessment of a screening tool.
    Allen C; Zarowitz B; O'Shea T; Peterson E; Yonan C; Waterman F
    Geriatr Nurs; 2018; 39(1):54-59. PubMed ID: 28807457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current concepts in the pharmacotherapy of pseudobulbar affect.
    Pioro EP
    Drugs; 2011 Jun; 71(9):1193-207. PubMed ID: 21711063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect.
    Haiman G; Pratt H; Miller A
    J Clin Psychopharmacol; 2009 Oct; 29(5):444-52. PubMed ID: 19745644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.